+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Immunotherapy in Urology, An Issue of Urologic Clinics. The Clinics: Surgery Volume 47-4

  • Book

  • October 2020
  • Elsevier Health Science
  • ID: 5130680

The Guest Editors of this issue of Urologic Clinics of North America have put together a comprehensive collection of articles that provides the current knowledge on urologic cancer immunotherapy. Expert authors have contributed clinical review articles on the following topics: Era of personalized vaccines for GU cancers; TCR and dendritic vaccine platforms for GU cancers; Neo-adjuvant platforms for GU cancer immunotherapy; Immune-editing in Cancer: Role of tumor microenvironment and immune-suppressive pathways in localized and aggressive disease; Clinical integration of neo-adjuvant platforms for prostate cancer immunotherapy; Immunotherapy for muscle and non-muscle invasive bladder cancer: BCG and beyond; Immunotherapy for metastatic bladder cancer; Immunotherapy options for metastatic castrate-resistant prostate cancer; Role of tissue infiltrating lymphocytes: Understanding TCR; Therapeutic platforms for IPSC-derived CAR-T; Immune-suppression in prostate cancer: Underlying causes and influence on response to immunotherapy; and Racial disparity in response to immunotherapy. Urologists will come away with the most current information they need to improve outcomes in the urologic cancer patient.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Authors

Sujit S Nair Ashutosh Tewari